The Future of Precision Medicine in Oncology

Millner, Lori M.; Strotman, Lindsay N.

doi:10.1016/j.cll.2016.05.003

Cited by 43 publications

(26 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diagnostic (associated with the presence of a specific pathophysiological state), prognostic (associated with disease outcome), and predictive (associated with drug response) cancer biomarkers guide clinical treatment decisions and direct the use of drugs that modulate the activity of the specific actionable target. 1 , 2 …”

Section: Introductionmentioning

confidence: 99%

Fishing for cures: The alLURE of using zebrafish to develop precision oncology therapies

et al. 2017

View full text Add to dashboard Cite

Zebrafish have proven to be a valuable model to study human cancer biology with the ultimate aim of developing new therapies. Danio rerio are amenable to in vivo imaging, high throughput drug screening, mutagenesis, and transgenesis, and they share histological and genetic similarities with Homo sapiens. The significance of zebrafish in the field of precision oncology is rapidly emerging. Indeed, modeling cancer in zebrafish has already been used to identify tumor biomarkers, define therapeutic targets and provide an in vivo platform for drug discovery. New zebrafish studies are starting to pave the way to direct individualized clinical applications. Patient-derived cancer cell xenograft models have demonstrated the feasibility of using zebrafish as a real time avatar of prognosis and drug response to identify the most ideal therapy for an individual patient. Genetic cancer modeling in zebrafish, now facilitated by rapidly evolving genome editing techniques, represents another innovative approach to recapitulate human oncogenesis and develop individualized treatments. Utilizing zebrafish to design customizable precision therapies will improve the clinical outcome of patients afflicted with cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Fishing for cures: The alLURE of using zebrafish to develop precision oncology therapies

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Oncology also employs a staging system that allow for risk stratification, prediction of outcomes and the appropriate selection of therapeutic treatments for a corresponding stage. This has allowed Oncology to move toward personalized medicine using biomarkers and genomics to identify and personalize cancer care for patients …”

mentioning

confidence: 99%

“…This has allowed Oncology to move toward personalized medicine using biomarkers and genomics to identify and personalize cancer care for patients. 6,7 The goal of this study is to articulate a standardized aggregate outcome reporting method for chronic wounds. To achieve this objective, we analyze healing rates form a large database of wound healing outcomes generated by a wound care management company (Healogics, Jacksonville, FL) operating 626 acute care hospital based wound care clinics and subsequently compare the results to healing outcomes at an academic clinical team working at a satellite, hospital-based wound clinic.…”

mentioning

confidence: 99%

Wound healing outcomes: Using big data and a modified intent‐to‐treat method as a metric for reporting healing rates

Ennis

Hoffman²,

Gurtner

et al. 2017

Wound Repair Regeneration

View full text Add to dashboard Cite

Chronic wounds are increasing in prevalence and are a costly problem for the US healthcare system and throughout the world. Typically outcomes studies in the field of wound care have been limited to small clinical trials, comparative effectiveness cohorts and attempts to extrapolate results from claims databases. As a result, outcomes in real world clinical settings may differ from these published studies. This study presents a modified intent-to-treat framework for measuring wound outcomes and measures the consistency of population based outcomes across two distinct settings. In this retrospective observational analysis, we describe the largest to date, cohort of patient wound outcomes derived from 626 hospital based clinics and one academic tertiary care clinic. We present the results of a modified intent-to-treat analysis of wound outcomes as well as demographic and descriptive data. After applying the exclusion criteria, the final analytic sample includes the outcomes from 667,291 wounds in the national sample and 1,788 wounds in the academic sample. We found a consistent modified intent to treat healing rate of 74.6% from the 626 clinics and 77.6% in the academic center. We recommend that a standard modified intent to treat healing rate be used to report wound outcomes to allow for consistency and comparability in measurement across providers, payers and healthcare systems.

show abstract

“…In 2004, US Food and Drug Administration approved the clinical use of CellSearch system (Veridex) for CTC detection in epithelial cancer types such as breast [28], colorectal [29] and prostate cancer [30] for purposes of prognostication. This system uses immunomagnetic and fluorescence imaging technology to enrich and enumerate CTCs from 7.5 ml of whole blood based on the expression of specific proteins in CTCs [31,32]. CTCs are first separated from other blood cells using magnetic iron nanoparticles coated with antibodies targeted against EpCAM (an epithelial cell adhesion molecule present on the cell surface of CTCs).…”

Section: Use Of Microfluidics In Ctc Enrichmentmentioning

confidence: 99%

Profiling Circulating Tumour Cells for Clinical Applications

Goh¹,

Lim²

2019

Liquid Biopsy

View full text Add to dashboard Cite

Circulating tumour cells (CTCs) refer to cells found in the peripheral blood, which are derived from the primary or secondary tumour. They serve as an alternative to study the biology of the primary tumour especially when tissue biopsy is not available. However, major challenges in CTC analysis are the rarity of these cells and the purity of the isolated population. The advancement in technologies allows detection and enrichment of sufficiently pure CTCs at the single-cell level, facilitating downstream molecular characterisation. Single CTC analysis allows detection of key mutations that may be critical to disease management and helps to address the intercellular differences among tumour cells. In this chapter, we discuss the technologies for CTC isolation and the use of CTCs in achieving early detection and prognosis of cancer, real-time monitoring of cancer therapy and tailoring of personalised treatments.

show abstract

The Future of Precision Medicine in Oncology

Cited by 43 publications

References 39 publications

Fishing for cures: The alLURE of using zebrafish to develop precision oncology therapies

Fishing for cures: The alLURE of using zebrafish to develop precision oncology therapies

Wound healing outcomes: Using big data and a modified intent‐to‐treat method as a metric for reporting healing rates

Profiling Circulating Tumour Cells for Clinical Applications

Contact Info

Product

Resources

About